aTyr Pharma Q1 EPS $(0.23) Beats $(0.24) Estimate, Sales $235.00K Beat $20.00K Estimate

5/2/24 4:27:04 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $LIFE alert in real time by email

aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 20.69 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $235.00 thousand which beat the analyst consensus estimate of $20.00 thousand by 1.08K percent.

Get the next $LIFE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LIFE

Date	Price Target	Rating	Analyst
7/5/2023		Outperform → Perform	Oppenheimer
11/11/2021	$18.00 → $11.00	Buy	HC Wainwright & Co.
11/11/2021	$18.00 → $11.00	Action List Buy	HC Wainwright & Co.
10/12/2021	$22.00	Outperform	RBC Capital
9/21/2021	$19.00	Overweight	Piper Sandler
9/14/2021	$20.00 → $21.00	Buy	Roth Capital
9/14/2021	$14.00 → $20.00	Outperform	Oppenheimer
9/13/2021	$13.00 → $18.00	Buy	HC Wainwright & Co.

More analyst ratings

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from "LIFE" to "ATYR"
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will be changing its ticker symbol from "LIFE" to "ATYR." Effective at the market open on June 5, 2024, the Company's common stock will trade on the Nasdaq Capital Market under the new symbol "ATYR." "As we advance our lead therapeutic candidate, efzofitimod, through a pivotal Phase 3 study in pulmonary sarcoidosis and prepare for potential commercialization, the "ATYR" ticker symbol is a strong reflec
6/3/24 8:00:00 AM ET
$LIFE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 24, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 9,400 shares of aTyr's common stock, each with an exercise price of $1.86 per share, which is equal to the closing price of aTyr's common stock on the Nasdaq Capital Market on May 22, 2024, the effective date of the grants. These stock awards were granted as an inducement material
5/24/24 4:00:00 PM ET
$LIFE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2024 International Conference, which is scheduled to take place May 17 – 22 in San Diego, CA. "These findings further demonstrate the unique way in which efzofitimod is modulating myeloid cells to confer the anti-inflammatory benefits we have seen in patients with pulmonary sarcoidosis, a major form o
5/15/24 7:00:00 AM ET
$LIFE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$LIFE
Leadership Updates

Live Leadership Updates

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Wayne A. I. Frederick, M.D., as an advisor to the company. Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023. "We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Dr. Frederick's clinical background combined with
1/18/24 8:00:00 AM ET
$LIFE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources
SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Danielle Campbell to Vice President, Human Resources. Ms. Campbell will serve as a member of the company's executive leadership team and oversee all aspects of human resources strategies and functions, including organizational development, talent management and talent acquisition initiatives. "We are delighted to welcome Danielle to aTyr at a pivotal time in the company's journey as we expand our team to support our next phase of growth," said Sanjay S.
12/24/21 8:02:00 AM ET
$LIFE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors
NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ
11/2/21 9:00:00 AM ET
$AMGN
$APVO
$BCTX
$BMY
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations

$LIFE
Financials

Live finance-specific insights

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged
3/14/24 4:00:00 PM ET
$LIFE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 14, 2024Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI834bef07b22642ae8be51b7
2/28/24 8:00:00 AM ET
$LIFE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results
SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate update after the market close on Thursday, March 9, 2023. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 9, 2023Time: 5:00 p.m. EST / 2:00 p.m. PSTDial-In Registration: https://register.vevent.com/register/BI01f8362bebee42539116051
3/2/23 8:00:00 AM ET
$LIFE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

aTyr Pharma Q1 EPS $(0.23) Beats $(0.24) Estimate, Sales $235.00K Beat $20.00K Estimate

Chat with this insight

Recent Analyst Ratings for $LIFE

$LIFE Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Denyes Nancy bought $9,276 worth of shares (5,000 units at $1.86), increasing direct ownership by 29% to 22,267 units (SEC Form 4)

Coughlin Timothy bought $87,500 worth of shares (50,000 units at $1.75) (SEC Form 4)

Broadfoot Jill Marie bought $8,950 worth of shares (5,000 units at $1.79), increasing direct ownership by 22% to 27,960 units (SEC Form 4)

$LIFE Large Ownership Changes

This live feed shows all institutional transactions in real time.

$LIFE Market Insights

Live Market Insights

$LIFE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$LIFE Press Releases

Fastest customizable press release news feed in the world

SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change From "LIFE" To "ATYR", Effective At The Market Open On June 5, 2024

HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target

aTyr Pharma Says DSMB Recommended Ongoing Phase 3 EFZO-FIT Study Of Efzofitimod Continue Without Any Modifications

Denyes Nancy bought $9,276 worth of shares (5,000 units at $1.86), increasing direct ownership by 29% to 22,267 units (SEC Form 4)

Coughlin Timothy bought $87,500 worth of shares (50,000 units at $1.75) (SEC Form 4)

Broadfoot Jill Marie bought $8,950 worth of shares (5,000 units at $1.79), increasing direct ownership by 22% to 27,960 units (SEC Form 4)

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from "LIFE" to "ATYR"

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

$LIFE Leadership Updates

Live Leadership Updates

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources

BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

$LIFE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

aTyr Pharma downgraded by Oppenheimer

HC Wainwright & Co. reiterated coverage on aTyr Pharma with a new price target

HC Wainwright & Co. reiterated coverage on aTyr Pharma with a new price target

$LIFE Financials

Live finance-specific insights

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results

$LIFE SEC Filings

aTyr Pharma Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by aTyr Pharma Inc.

aTyr Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Recent Analyst Ratings for
$LIFE

$LIFE
Insider Purchases

$LIFE
Large Ownership Changes

$LIFE
Market Insights

$LIFE
Insider Trading

$LIFE
Press Releases

$LIFE
Leadership Updates

$LIFE
Analyst Ratings

$LIFE
Financials

$LIFE
SEC Filings